Details of Disease

General Information of Disease (ID: DISOBM0Q)

• Disease Name: Sleep-wake disorder
• Synonyms: wake disorders, sleep; wake disorder, sleep; tachypnea, sleep-related neurogenic; syndromes, short sleeper; syndromes, long sleeper; syndromes, Subwakefullness; syndrome, short sleeper; syndrome, long sleeper; syndrome, Subwakefullness; sleeper syndromes, short; sleeper syndromes, long; sleeper syndrome, short; sleeper syndrome, long; sleep-related neurogenic tachypnea; sleep-related neurogenic Tachypneas; sleep related neurogenic tachypnea; sleep phenotypes, short; sleep disorders; sleep disorder; short sleeper syndromes; short sleeper syndrome; short sleep phenotypes; short sleep phenotype; phenotypes, short sleep; phenotype, short sleep; non-organic sleep disorder; neurogenic tachypnea, sleep-related; neurogenic Tachypneas, sleep-related; long sleeper syndromes; long sleeper syndrome; disturbed nyctohemeral rhythm; disorders, sleep wake; disorders, sleep; disorders of the sleep-wake schedule; disorder, sleep wake; disorder, sleep; disorder of sleep-wake schedule; circadian dysregulation; Tachypneas, sleep-related neurogenic; Subwakefullness syndromes; Subwakefullness syndrome; sleep wake disorder; disorder of sleep-wake cycle
• Disease Class: 7A00-7B2Z: Sleep-wake disorder
• Definition: Abnormal sleep-wake schedule or pattern associated with the circadian rhythm which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.
• Disease Hierarchy:
  DIS3JP1U: Sleep disorder
  DISOBM0Q: Sleep-wake disorder
• ICD Code: ICD-11: ICD-11: 7A00-7B2Z
• Disease Identifiers:
  MONDO ID: MONDO_0003406
  MESH ID: D020178
  UMLS CUI: C0877792
  MedGen ID: 167920
  SNOMED CT ID: 271794005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aceprometazine	DM1SRQT	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 9 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
M100907	DM7ZFBA	Phase 3	Small molecular drug	[2]
SR46349B	DM1ODMR	Phase 3	Small molecular drug	[3]
Adipiplon	DM821BS	Phase 2	Small molecular drug	[4]
Evt201	DM8QXEY	Phase 2	Small molecular drug	[5]
KRL-103	DMQ76P5	Phase 2	NA	[6]
NELOTANSERIN	DM4LKFO	Phase 2	Small molecular drug	[7]
PRUVANSERIN	DMM7F1E	Phase 2	Small molecular drug	[8]
VSF-173	DM3WJ9D	Phase 2	NA	[9]
APD-916	DMRGF9Q	Phase 1	NA	[10]

This Disease is Treated as An Indication in 5 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SAR-152954	DM7OR48	Discontinued in Phase 1	NA	[11]
Almorexant	DMQALR5	Terminated	Small molecular drug	[12]
Luzindole	DMXRJQV	Terminated	Small molecular drug	[13]
S-20928	DMQDWMJ	Terminated	Small molecular drug	[14]
SB-269970	DM8WTGA	Terminated	Small molecular drug	[15]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
COL-204	DMCQUAR	Investigative	NA	[16]
EVT-501	DM4Q2HZ	Investigative	NA	[17]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
RORC	TTGV6LY	Strong	Biomarker	[18]

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AANAT	OTUBJ7SX	Strong	Biomarker	[19]
BHLHE40	OTITX14U	Strong	Biomarker	[18]
NFIL3	OTQH9HM3	Strong	Biomarker	[18]

References

• [1] Drug information of Aceprometazine, 2008. eduDrugs.
• [2] ClinicalTrials.gov (NCT00495885) Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus. U.S. National Institutes of Health.
• [3] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [4] ClinicalTrials.gov (NCT00683436) Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT00380003) Efficacy Study of EVT 201 to Treat Insomnia. U.S. National Institutes of Health.
• [6] Pharmaceutical Research Companies Are Developing Nearly 200 Medicines to Treat Mental Illnesses and Addictive Disorders. Pharmaceutical Research and Manufacturers of America report. 2012.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021795)
• [8] ClinicalTrials.gov (NCT00259311) Efficacy Study of LY2422347 to Treat Insomnia. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT00467441) VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT01093508) Single-dose Safety Study of APD916 in Healthy Volunteers. U.S. National Institutes of Health.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033674)
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2886).
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1363).
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1360).
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3233).
• [16] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
• [18] Circadian polymorphisms in night owls, in bipolars, and in non-24-hour sleep cycles.Psychiatry Investig. 2014 Oct;11(4):345-62. doi: 10.4306/pi.2014.11.4.345. Epub 2014 Oct 20.
• [19] Significant association of the arylalkylamine N-acetyltransferase ( AA-NAT) gene with delayed sleep phase syndrome.Neurogenetics. 2003 Apr;4(3):151-3. doi: 10.1007/s10048-002-0141-9. Epub 2002 Nov 29.